<DOC>
	<DOCNO>NCT00414024</DOCNO>
	<brief_summary>This study evaluate safety efficacy Tegaserod opioid-induced constipation patient non-cancer pain . Patients enter study PRIOR core study ( CHTF919N2201 ) interim analysis receive treatment follow : Patients randomly assign receive open label tegaserod 6 mg b.i.d . tegaserod 12 mg o.d . use allocation ratio 1:1 . Patients enter study AFTER core study interim analysis receive treatment follow : Patients assign receive select tegaserod dose regimen ( determine core study interim analysis ) open label fashion .</brief_summary>
	<brief_title>Safety Efficacy Tegaserod Opioid-induced Constipation Patients With Non-cancer Pain .</brief_title>
	<detailed_description />
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Analgesics , Opioid</mesh_term>
	<mesh_term>Tegaserod</mesh_term>
	<criteria>Male female outpatient 18 year age old . Patients chronic noncancer pain necessitates use non injectable opioid analgesic . Chronic pain present minimum 3 month need chronic use opioids pain relief . Constipation , accord investigator 's clinical judgment , result opioid use noncancer chronic pain . Opioidinduced Constipation ( OIC ) define follow : less 3 spontaneous bowel movement per week least one follow least 25 % occasion : 1 . Hard hard stool 2. sensation incomplete evacuation 3. strain bowel movement 1. Who receive opioids abdominal pain connective tissue disorder . Planned discontinuation opioids study Who undergo major surgery within 3 month prior screen . With history prior chronic constipation ( CC ) present three month relate opioid use . With current diagnosis irritable bowel syndrome ( IBS ) constipation predominant alternator . With previous use tegaserod within 3 month prior baseline . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Opioid , constipation , tegaserod</keyword>
</DOC>